Back to top
more

Legend Biotech (LEGN)

(Delayed Data from NSDQ)

$21.82 USD

21.82
1,424,109

+0.56 (2.63%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $21.82 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Company News for Nov 13, 2025

by Zacks Equity Research

Companies in The News Are: LEGN, ONON, PLTR, ALC

Zacks Equity Research

CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Company News for Aug 12, 2025

by Zacks Equity Research

Companies In The News Are: MU, AAON, LEGN, FNV.

Zacks Equity Research

Key Inflation Data in Focus

by Zacks Equity Research

Key Inflation Data in Focus.

Zacks Equity Research

Pre-Markets in Green, Inflation Data, Retail Sales, Q2 Earnings This Week

by Zacks Equity Research

U.S. stock futures edged higher this morning after an impressive last week.

Zacks Equity Research

Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

What Makes Legend Biotech (LEGN) a New Buy Stock

by Zacks Equity Research

Legend Biotech (LEGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

by Zacks Equity Research

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.